Catalent (NYSE:CTLT) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com assumed coverage on shares of Catalent (NYSE:CTLT) in a report issued on Sunday. The brokerage set a “sell” rating on the stock.

A number of other equities research analysts have also weighed in on the stock. Royal Bank of Canada reissued a “sector perform” rating and set a $63.50 price objective on shares of Catalent in a report on Tuesday, February 20th. UBS Group restated a “neutral” rating and issued a $63.50 price objective (up from $58.00) on shares of Catalent in a research note on Tuesday, February 6th. Barclays upped their target price on Catalent from $45.00 to $47.00 and gave the company an “equal weight” rating in a research report on Thursday, January 25th. Finally, Stephens restated an “equal weight” rating and set a $63.50 price objective on shares of Catalent in a research note on Thursday, April 4th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $52.46.

Catalent Price Performance

Shares of CTLT opened at $56.50 on Friday. The company has a 50 day moving average of $56.47 and a two-hundred day moving average of $49.04. The company has a market cap of $10.23 billion, a price-to-earnings ratio of -8.31, a price-to-earnings-growth ratio of 6.08 and a beta of 1.18. The company has a quick ratio of 1.73, a current ratio of 2.48 and a debt-to-equity ratio of 1.34. Catalent has a twelve month low of $31.45 and a twelve month high of $60.20.

Catalent (NYSE:CTLT) last posted its quarterly earnings data on Friday, February 9th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.22). Catalent had a negative return on equity of 2.43% and a negative net margin of 29.91%. The business had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same period in the previous year, the business earned $0.62 EPS. The firm’s revenue for the quarter was down 10.2% compared to the same quarter last year. As a group, analysts predict that Catalent will post 0.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Catalent

Hedge funds have recently modified their holdings of the company. Daiwa Securities Group Inc. raised its holdings in Catalent by 8.3% in the 1st quarter. Daiwa Securities Group Inc. now owns 26,397 shares of the company’s stock worth $1,490,000 after purchasing an additional 2,017 shares during the period. Nordea Investment Management AB raised its stake in shares of Catalent by 10.2% during the 1st quarter. Nordea Investment Management AB now owns 11,874 shares of the company’s stock worth $672,000 after buying an additional 1,096 shares during the period. BNP Paribas Financial Markets raised its stake in shares of Catalent by 154.6% during the 1st quarter. BNP Paribas Financial Markets now owns 216,311 shares of the company’s stock worth $12,211,000 after buying an additional 131,360 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Catalent by 33.8% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,789 shares of the company’s stock valued at $1,230,000 after buying an additional 5,499 shares in the last quarter. Finally, Diversify Advisory Services LLC acquired a new stake in Catalent in the 1st quarter valued at $1,040,000.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.